SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors analyze the company's shift to becoming a net buyer of stocks, alongside robust Q2 earnings and aggressive share repurchases. Community sentiment is mixed, with some highlighting the massive cash pile as a defensive advantage, while others criticize the lack of dividend growth and slow capital deployment compared to high-growth technology sectors.

Happen, Inc. is a U.S. digital marketplace bank focused on the Motivated Middle high FICO, high-income borrowers actively managing their financial lives. The firm’s success is fueled by advanced credit underwriting, a proprietary technology platform, and a marketplace bank model that generates compelling revenue through loan sales, net interest income, and fee-based services. It operates through the LendingClub Bank and LendingClub Corporation (Parent Only) segments. The LendingClub Bank segment is involved in the provision of a full complement of financial products and solutions, loans, leases, and deposits. The LendingClub Corporation (Parent Only) segment includes the holding company legal entity. The company was founded by Renaud Laplanche and Soulaiman Htite on October 2, 2006 and is headquartered in San Francisco, CA.

Happen Inc.

Happen Inc. is capturing investor interest following strong earnings performance and positive management guidance on loan originations. Community members are actively debating the company's valuation, the potential impact of share buybacks, and its positioning within the digital banking and AI-driven financial services sector.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

Investors are increasingly rotating into $SGOV as a safe haven for cash to earn competitive yields while avoiding market volatility. The community is actively discussing the ETF as a strategic tool for capital preservation amidst concerns over economic uncertainty and the broader debt environment.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is generating significant community buzz as investors highlight its potential to act as a sovereign cloud infrastructure for AI agents and decentralized applications. Discussion is centered on the shift from speculation to utility, with many actively loading up at current price levels while monitoring key technological developments like cloud engines and AI integration.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

Investors are actively debating the legitimacy and financial performance of Trump-affiliated crypto assets, with many users pointing to significant value declines as evidence of a potential scam or rug pull. The conversation is polarized between supporters who see the coins as a unique investment opportunity and critics highlighting large-scale losses and potential conflicts of interest tied to official disclosures.

BitGo Holdings, Inc. operates as a digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. It focuses on accelerating the transition of the financial system to a digital asset economy. The company was founded by Michael Belshe and Ben Davenport in 2013 and is headquartered in Sioux Falls, SD.

BitGo Holdings Inc. - Ordinary Shares - Class A

Investors are actively debating whether BitGo represents an undervalued institutional infrastructure play poised for a recovery, or a struggling post-IPO stock suffering from intense short-selling pressure. Market sentiment remains divided between those loading up on shares due to the company's recent share buyback and regulatory positioning, and skeptics who are wary of its downward price trend and past earnings volatility.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is capturing investor interest as a leveraged play on gold, bolstered by momentum in the mining sector and optimistic anticipation ahead of upcoming earnings. Community sentiment remains focused on the company's dual-commodity exposure to gold and copper, with active discussions surrounding potential value-unlocking corporate restructuring and strategic growth initiatives.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics ($DFTX) is experiencing significant market interest and high volatility as investors position themselves ahead of critical Phase 3 clinical trial readouts. The community is actively debating the potential outcomes, with sentiment heavily influenced by the company's strong cash position and the high-stakes nature of these upcoming trial results for its generalized anxiety and depressive disorder treatments.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending following reports that the conglomerate initiated a multi-billion dollar stake in Alphabet, signaling a strategic shift toward major technology investments. Community discussion is heavily focused on what this move suggests for the company's direction under new leadership and its massive cash pile.

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis Inc - Ordinary Shares - Class A

Zoetis is trending as investors react to the company's recent earnings performance and updated fiscal guidance, with the community closely debating its long-term growth potential in the animal health sector. Market participants are actively discussing the stock's valuation, institutional positioning, and the resilience of pet-care spending amidst broader economic uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors in Xeris Biopharma are closely tracking the upcoming earnings report while closely monitoring the progression of the XP-8121 Phase 3 trial and Recorlev's revenue trajectory. The community is actively discussing the potential for a valuation rerating as the company shifts toward sustained profitability and expands its market footprint in specialty medicine.

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026. "The...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results...

Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?

Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris Board of...

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity...

Xeris Announces Updates to Its Board of Directors

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its Board of Directors appointed John Shannon to Chair of the Board...

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS

Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States...

Xeris Biopharma Announces Private Exchange of Convertible Notes

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements...

$XERS Q2 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.18 down -1700.00% YoY
• Reported revenue of $92.1M up 28.74% YoY
• Xeris Biopharma Holdings tightened its full-year 2026 total revenue guidance to a range of $385 million to $390 million, reflecting the company&#39;s confidence in its portfolio and business trajectory.

Stocktwits

Xeris Biopharma Holdings Inc

 Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.18 down -1700.00% YoY
• Reported revenue of $92.1M up 28.74% YoY
• Xeris Biopharma Holdings tightened its full-year 2026 total revenue guidance to a range of $385 million to $390 million, reflecting the company's confidence in its portfolio and business trajectory.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$XERS Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.18 down -1700.00% YoY
• Reported revenue of $92.1M up 28.74% YoY
• Xeris Biopharma Holdings tightened its full-year 2026 total revenue guidance to a range of $385 million to $390 million, reflecting the company's confidence in its portfolio and business trajectory.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

Equity

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

XERSXeris Biopharma Holdings Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest XERS News